Loading clinical trials...
Loading clinical trials...
A Phase III Multi-center, Open-label, Follow-up Study, to Assess the Safety and Efficacy of Liquid Certolizumab Pegol as Additional Medication to Methotrexate, in the Treatment of Signs and Symptoms and in the Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis Who Participated in Study CDP870-050
Conditions
Interventions
Certolizumab Pegol
Locations
67
United States
172
Palm Desert, California, United States
185
Pasadena, California, United States
170
Santa Maria, California, United States
194
Whittier, California, United States
176
Naples, Florida, United States
186
Palm Harbor, Florida, United States
Start Date
November 1, 2005
Primary Completion Date
February 1, 2012
Completion Date
February 1, 2012
Last Updated
March 27, 2020
NCT06329401
NCT07048197
NCT07484243
NCT06647069
NCT06841562
NCT07268326
Lead Sponsor
UCB Pharma
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions